Immune to Cancer: The CRI Blog
-
CRI Congratulates 2016 Lasker Award Winners
The Albert and Mary Lasker Foundation announced the 2016 recipients of the prestigious Lasker Awards, and CRI congratulates Charles…
-
Immunotherapy Patient Summit Agenda – Announced!
#CRISummit16 promises to be an educational and empowering day for cancer patients and their families.
-
FDA Approves Pembrolizumab (Keytruda®), a PD-1 Antibody, for Head and Neck Cancer
New hope now exists for patients with advanced head and neck cancer.
-
Cancer Research Institute Featured in New York Times Cover Story on Cancer Immunotherapy
The pioneering work of CRI and its funded scientists are profiled in this special feature from the…
-
LabAnswer and Its Employees Raise More Than $50,000 for CRI
In January of 2016, CRI formed a new corporate philanthropy partnership with LabAnswer, the largest independent laboratory…
-
Announcing CRI’s Immunotherapy Patient Summit
This fall, CRI is bringing something very new to our patient community: our first-ever Immunotherapy Patient Summit,…
-
Ready. Raise. Rise. for CRI!
For the second year, CRI is participating in the Bristol-Myers Squibb Ready. Raise. Rise.™ Campaign to raise…
-
CRI Scientist Receives Russian Federation National Award
Sergei Nedospasov, PhD, D.Sc., was honored for his contributions to the molecular mediators of immunity, including work…
-
Have an Autoimmune Disease? You Still May Be Able To Receive Cancer Immunotherapy
A retrospective study finds that immunotherapies are safe and work in many patients with preexisting autoimmune diseases.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.